Switch to Triumeq — Competitive Intelligence Brief

Switch to Triumeq (Switch to Triumeq) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination therapy (NRTI + INSTI). Area: Infectious Disease / Virology.

marketed Antiretroviral combination therapy (NRTI + INSTI) HIV reverse transcriptase, HIV integrase Infectious Disease / Virology Small molecule

Target snapshot

Switch to Triumeq (Switch to Triumeq) — McGill University Health Centre/Research Institute of the McGill University Health Centre. Triumeq is a fixed-dose combination antiretroviral that inhibits HIV reverse transcriptase and integrase to suppress viral replication.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Switch to Triumeq TARGET	Switch to Triumeq	McGill University Health Centre/Research Institute of the McGill University Health Centre	marketed	Antiretroviral combination therapy (NRTI + INSTI)	HIV reverse transcriptase, HIV integrase
DOR/DTG/3TC	DOR/DTG/3TC	Insel Gruppe AG, University Hospital Bern	marketed	Antiretroviral combination (NNRTI + INSTI + NRTI)	HIV reverse transcriptase, HIV integrase
Immediate switch to TDF/FTC/RPV	Immediate switch to TDF/FTC/RPV	Azienda Ospedaliera San Gerardo di Monza	marketed	Antiretroviral combination therapy (NRTI/NNRTI)	HIV reverse transcriptase, HIV integrase
Atripla (r)	Atripla (r)	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	marketed	Antiretroviral combination (NNRTI + NRTI + NtRTI)	HIV reverse transcriptase, HIV integrase
Tenofovir, lamivudine and efavirenz	Tenofovir, lamivudine and efavirenz	Centre for the AIDS Programme of Research in South Africa	marketed	Antiretroviral combination therapy (NRTI/NtRTI + NNRTI)	HIV reverse transcriptase, HIV integrase
TDF/3TC/EFV or DTG or NVP	TDF/3TC/EFV or DTG or NVP	MU-JHU CARE	marketed	Antiretroviral combination therapy (NRTI + NNRTI or INSTI)	HIV reverse transcriptase, HIV integrase
Antiretroviral therapy	Antiretroviral therapy	ANRS, Emerging Infectious Diseases	marketed	Combination antiretroviral therapy (multiple classes: nucleoside/nucleotide reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, integrase strand transfer inhibitors, entry inhibitors)	HIV reverse transcriptase, HIV integrase, HIV protease, HIV envelope glycoproteins (gp120/gp41), CCR5 co-receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination therapy (NRTI + INSTI) class)

1. Fenway Community Health · 1 drug in this class
2. McGill University Health Centre/Research Institute of the McGill University Health Centre · 1 drug in this class
3. ViiV Healthcare · 1 drug in this class